肥厚型心肌病患者心房颤动的预测因素
该多中心回顾性队列研究纳入4248例无心房颤动的肥厚型心肌病患者,随访至2008年,发现女性、年龄、左房内径、NYHA分级、高血压及血管疾病与心房颤动发生相关;心房颤动与不良预后相关,抗心律失常药物长期预防效果有限。
要点
- 女性、年龄、左房内径、NYHA分级、高血压及血管疾病是肥厚型心肌病患者发生心房颤动的预测因素。
- 心房颤动患者10年心血管死亡比例高于窦性心律患者(10.9% vs 4.9%)。
- β受体阻滞剂、钙通道拮抗剂和丙吡胺初期维持窦性心律但保护效应随时间减弱,胺碘酮未预防心房颤动。
核心结论
- 肥厚型心肌病患者发生心房颤动的风险可通过常规临床参数识别。
- 心房颤动的发生与不良预后相关,但抗心律失常治疗无长期预防心房颤动的证据。
研究设计与样本
- 回顾性纵向多中心队列研究,1986至2008年间在七个中心招募患者,纳入4248例无既往心房颤动的肥厚型心肌病患者。
- 采用多变量Cox回归模型拟合预设预测因素。
主要发现
- 中位随访期间740例(17.4%)达到主要终点(阵发性、永久性或持续性心房颤动)。
- 多变量Cox回归显示心房颤动与女性、年龄、左房内径、NYHA分级、高血压及血管疾病相关。
- 10年心血管死亡比例:窦性心律组4.9%,心房颤动组10.9%(差值5.9%,95%CI 4.1%至7.8%)。
- 10年非心血管死亡比例:窦性心律组3.2%,心房颤动组5.9%(差值2.8%,95%CI 0.1%至4.2%)。
- 意向性治疗倾向评分分析显示β受体阻滞剂、钙通道拮抗剂和丙吡胺初期维持窦性心律但保护效应随时间减弱;胺碘酮未预防心房颤动。
关键数值与推荐
- 肥厚型心肌病定义为不明原因肥厚(最大左心室壁厚度≥15 mm或符合已发表的家系性疾病诊断标准)。
- 心房颤动终点为心电图、动态心电图或植入设备监测到的阵发性、永久性或持续性心房颤动。
临床怎么用
- 可利用常规临床参数(女性、年龄、左房内径、NYHA分级、高血压、血管疾病)识别心房颤动高危的肥厚型心肌病患者。
- 对肥厚型心肌病患者应关注心房颤动的发生,因其与较差预后相关。
- 抗心律失常药物不宜用于长期预防心房颤动,因证据显示无持续保护效应。
局限性
- 回顾性研究设计可能引入偏倚。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Atrial fibrillation (AF) is associated with increased morbidity and mortality in patients with hypertrophic cardiomyopathy (HCM). The primary aim of this study (HCM Risk-AF) was to determine the predictors of AF in a large multicentre cohort of patients with HCM. Exploratory analyses were performed to investigate the association between AF and survival and the efficacy of antiarrhythmic therapy in maintaining sinus rhythm (SR). METHODS: A retrospective, longitudinal cohort of patients recruited between 1986 and 2008 in seven centres was used to develop multivariable Cox regression models fitted with preselected predictors. HCM was defined as unexplained hypertrophy (maximum left ventricular wall thickness of ≥15 mm or in accordance with published criteria for the diagnosis of familial disease). 28% of patients (n=1171) had coexistent hypertension. The primary end point was paroxysmal, permanent or persistent AF detected on ECG, Holter monitoring or implantable device interrogation. RESULTS: Of the 4248 patients with HCM without pre-existing AF, 740 (17.4%) reached the primary end point. Multivariable Cox regression revealed an association between AF and female sex, age, left atrial diameter, New York Heart Association (NYHA) class, hypertension and vascular disease. The proportion of patients with cardiovascular death at 10 years was 4.9% in the SR group and 10.9% in the AF group (difference in proportions=5.9%; 95% CI (4.1% to 7.8%)). The proportion of patients with non-cardiovascular death at 10 years was 3.2% in the SR group and 5.9% in the AF group (difference in proportions=2.8%; 95% CI (0.1% to 4.2%)). An intention-to-treat propensity score analysis demonstrated that β-blockers, calcium channel antagonists and disopyramide initially maintained SR during follow-up, but their protective effect diminished with time. Amiodarone therapy did not prevent AF during follow-up. CONCLUSION: This study shows that patients with HCM who are at risk of AF development can be identified using readily available clinical parameters. The development of AF is associated with a poor prognosis but there was no evidence that antiarrhythmic therapy prevents AF in the long term.
引用
- Guttmann OP, Pavlou M, O'Mahony C, et al. Predictors of atrial fibrillation in hypertrophic cardiomyopathy. Heart. 2016. PMID: 27794017. doi:10.1136/heartjnl-2016-309672
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。